Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Valirx Plc LSE:VAL London Ordinary Share GB00BLH13C52 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  -1.10 -6.88% 14.90 1,117,086 16:35:27
Bid Price Offer Price High Price Low Price Open Price
14.50 15.00 16.00 14.25 16.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.54 -3.81 13
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:27 UT 7,866 14.90 GBX

Valirx (VAL) Latest News

More Valirx News
Valirx Investors    Valirx Takeover Rumours

Valirx (VAL) Discussions and Chat

Valirx Forums and Chat

Date Time Title Posts
28/9/202216:30VALIRX - A Significantly Undervalued Pharma6,294
08/8/202215:25Valirx May 1st 2020 a New era begins2,131
26/4/202218:26RAINMAKER'S VALUE THREAD8,506
20/10/202119:02BITCOIN TRADING1
15/10/202116:26VALUE-

Add a New Thread

Valirx (VAL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
15:35:2714.907,8661,172.03UT
15:28:5514.882,500372.00O
15:13:1314.5070,00010,150.00O
15:10:1114.7915,0002,217.75O
15:07:3415.00150,00022,500.00O
View all Valirx trades in real-time

Valirx (VAL) Top Chat Posts

Top Posts
Posted at 28/9/2022 09:20 by Valirx Daily Update
Valirx Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker VAL. The last closing price for Valirx was 16p.
Valirx Plc has a 4 week average price of 10.75p and a 12 week average price of 10.35p.
The 1 year high share price is 64p while the 1 year low share price is currently 10.25p.
There are currently 90,174,156 shares in issue and the average daily traded volume is 860,017 shares. The market capitalisation of Valirx Plc is £13,300,688.01.
Posted at 13/9/2022 17:30 by livedata21
Cenkos would have to pay 22p per share. The cash goes to the company as they are buying shares.There is no point Cenkos buying shares at 22p when the share price is below that.They will probably buy when share price is much high - £2 etc.The profit is the difference.
Posted at 13/9/2022 12:57 by porky9
@francoismyname Have to say i have traded during this spike, rude not to. I don't short myself. But if you are short at 20p frankly its likely to pay off. even ignoring the obvious cash flow issues, should the share price rise above the Cenkos strike price of 22p they will cash out and the share price will fall like a stone. Cenkos results recently were sh@t they will be under pressure to increase fees. They will want the cash out to cover fees. Also, accepting BS aside, Nick would be a total bleeding idiot if he didn't sell half his recent 10p placement stock and be in for free on those. He already has a massive exposure before being forced to buy more to protect his investment and stop the business going bump. Thats what i would be doing for sure. It will be some years before the triple can bring in income, they need to raise shares for the lab and i still don't think THX will get funded. Even if they do it only delivers 1.8m over two years short term which is less than the running costs. See how events unfold. Can't argue though that those in the placement at 10p did well, fair play to them but a profit isn't a profit until its materialised. Good luck whatever your call
Posted at 07/9/2022 11:34 by jasonpugh
Incentive for share price increases. 1. Options yesterday’s rns (obvious really) 2. Cenkos warrants at 22p. 3. Director buys 4. Slaters buys. 5. Adams buys. 6. Confidence confirmation from suzy and dr sorensen about Theoremrx getting funds. Latest rns. 7. Kings college comments on breast cancer Incentive for share price decrease. 1. Porkys dribble lab placing fear at 7p lol(only the vulnerable sell on this pollution) 2. Franciscodimwit. Aka george followed porky. Lol Conclusion. 🧐 A sensible investor uses fundamental analysis therefore i fundamentally agree with the facts via rns. Not toxic mucus coming from the deramper squad.
Posted at 06/9/2022 07:57 by francoismyname
People seem to forget. A request was made at the AGM to make the options a bit difficult as no doubt the board would have issued them at 10p and to get more support for the directors. Now it’s the deal must be forthcoming if the options price is that high. People then getting 2+2 and now getting 5. Happy clappers on LSE saying deal must be imminent now as options are higher. No it’s just a follow through from the requests at the AGM. Don’t for christs sake buy in on this today. Ask yourself has VAL ever had a commercial deal in its 12 year exsistence, the answer is NO. This deal was meant to be done last Xmas. The share price is at 10p because it has not happened . If it were to happen very little up front payments and would you trust them to pay any future milestones when they can’t get circa £1m to Val for the first two years payments if the deal is done. I’d run to the hills before buying here. All jam tomorrow. No income whatsoever.
Posted at 23/8/2022 12:42 by porky9
Will See 6p Before we see 60p The situation is that Shareholders have a number of hurdles to overcome short term which is why I believe we will have further short-term downside: 1. There are 35m of shares recently issued at 10p I am going to estimate at least half of this is in non sticky hands just waiting for an increase in the bid to cash out at profit. Let’s call it 20m. They are in the hope that THX gets funded and a quick spike on the share price for them to cash out. There is 10% gain currently on the table with two MMs left that will deal at 11p. We need to offload this lot ASAP to move on. By my rough calculation about 8m of this is currently out so still some to offload. When the share price hits 10.5p some might just take it to avoid a loss situation. That’s the problem with placements, many are not in it to support the business longer term they are in it for a quick gain. 2. The 8.5m of director share options are not issued yet but I don’t see theses as an issue when they are as they will go into sticky hands. So just a little dilution. 3. I think they will need to issue the 20m additional shares asap to get the tCRO off the ground. As each day goes on, they are just burning more cash. The lab will change that situation but doing nothing about it currently. But it needs doing IMO. Based on past decisions and NOT adding to the BOD I expect much of the same. They will leave it until its too late again. THX will need more time and the longer they leave it the lower the placement for the lab will be. 4. Once we get over the above and the share price starts recovering CENKOS warrants will kick in after 22p and they will sell the lot flooding the market taking us down again. Just before this event, anyone left at 10p would sell half and be in for free with the rest to de-risk, that’s what I would do as its commercial sense not emotional sense. I think many think the THX position is going to change events and they will suddenly get funded. I don’t agree. I think it will take them years if not at all. It’s been nearly a year already. If it does land it only brings in 1.6m over two years from that point but it would help future working capital. Read the report directly from CENKOS on the research hub:- hxxps://www.cenkos.com/research-portal/#/portal/cenkos-securities/ GL PS - the H1 results should be out first week of Sept unless they delay it. It will show no further major progress in respect of 201 and continued cash burn of circa 110k a month. Until the lab gets started they have no immediate way to get cash in and getting the lab off the ground plus the board additions needs to happen ASAP IMO.
Posted at 15/8/2022 18:49 by jasonpugh
Cenkos warrants. Rns 25th aug 2021. Nearly 4 million shares exercisable at 22p share price Becomes active friday 25th aug. 10days from now. Is it possible do you think for share price to hit this figure soon baby? What a beautiful incentive for cenkos to raise share price from present ridiculous george Morris price of 12p. Ps. I know suzy ‘if only people would research the rns ‘s!’ Apologies for my accuracy. My brain derived neurotrophic factor has peaked. Pps. Hey nick. Champagne on ice just before your 20p top slicing becomes active or do you risk 21p 😆
Posted at 09/8/2022 05:02 by porky9
Oh, come off it Nick, gee whiz, It will be the best part of eight years plus before the kings deal delivers anything close to commercialisation and a load of phase trials along the way they would need to get right. Also, there is a drug already out TODAY for the triple: - https://www.independent.co.uk/news/health/trodelvy-nhs-breast-cancer-drug-b2122135.html so, it will be eight years too late, IF it ever proves successful. The success of VAL as it stands, depends entirely on 201 and at the moment that prize asset is now sitting with a sharp suit stateside trying to create a start up that has failed to deliver on the promised payments and NOT been called to task. So why am I currently negative? Because this business has so much dam potential yet the naivety of the BOD is shocking and in their current format I am not convinced that will change. I evidence this from: - The dire CENKOS warrants deal, still no II secured and just sold a pup. Leaving the placing until so far down the line that the business was at total risk of closure. Further back slapping at the update that the placing was a success after shafting shareholders royally and conveniently forgetting the THX service deal of 10k USD pcm from November to quote “that figure is plucked from the air” yet they confirmed the same to CENKOS just eight weeks or so earlier? and finally Kevin’s comment that Suzy is a “formidable negotiator” when it’s the one thing she is NOT strong at. You don’t know, what you don’t know and to carry on doing the same thing and expecting a different outcome is utter madness. IF they don’t act now, cash will burn down, and we will be back to another placing for more cash for working capital. Suzy was developing 201 for years at VALseek and it appears they are just happy to trudge on now that wages are secure for the next year, sorry but that’s how I see it. Despite the above, it can be turned around IMO: - They need TWO good board appointments to bolster the board and prevent similar mistakes going forward. The lab deal placing needs sorting as short-term pain now will result in SH gain later once revenues start flowing rather than relying on constant raises. Remove the exclusivity deal from THX and negotiate in parallel. In 9 mths THX can’t raise 2m and owe VAL 90k USD in unpaid service fees, time to call time on that. Don’t get me wrong Nick, in yours and Adams position I would have done exactly the same buying at 10p to protect your position, alternative was lights out and a total write off of your investment so your hand was forced but you now have 25m extra shares in issue at 10p not in sticky hands, that’s why the moment we see any share price uplift on the Bid its sold into. I also think 20m more shares will be issued shortly for the Lab and 8.5m in share options that’s a logical move imo hence why I believe we will see an share price dip short term. I await to see how events unfold. As I say, it can be turned around but personally I’m not buying at this this level if its business as usual. I want to see those Board appointments made. The P&D crew will ignore these failings but they need addressing. GL Pork's
Posted at 20/7/2022 16:09 by ben gibbons
And ameretto has the cheek to call me a paid ramper….. I think if anyone with a modicum of a brain cell looked back through my recent comments regarding Valrix I have not been ramping. I’ve consistently said that these tweets and comments on here from hot & cold stocks are probably fake and I’ve also said the share price won’t move until we get decent news again and I’ve also said the medium term for Val share price is 10-30. Amaretto your an idiot bro who talks utter nonsense…. Learn to read properly!
Posted at 09/7/2022 13:00 by porky9
@Jasonpugh You would have to ask that to Nick If I held the position Nick has I would do the same, but its a speculative play and he knows it, If the share price can rise to 15p which is possible over the next year he can sell those extra shares for a 50% gain and in doing so de-risk his position, that is sound business sense. That's what i would do. He is not stupid and i doubt "in love" with the stock as some are. Business is Business The risk factor on the downside SHORT TERM are four fold IMO:- 1. The board doesn't recognise their weaknesses which is really frustrating, appointments need to be made. Hopefully they come to their senses. If not things will carry on as before, that is a big risk. 2. THX haven't raised anything in 9mths and its now open ended, if its still like this in three months there will be more cash burn and they may need a plan B then and the market wont like it. 3. Bio Index is still a mess and outlook for funding dire, can change hopefully but will take time IMO and this will add downward pressure. 4. They are going to acquire a lab and that will cost money could be via further equity or debt. They have capacity to issue a further 20m shares and COULD use that which would create further short term dilution. They could also do another poor deal and we need to prevent that. I come back to point 1. For me this is critical to the success of VAL. I don't want to see another sh1t negotiation like CENKOS or THX milestone or not setting milestones on 301 with Japan either for that matter. The only way to prevent that is with new additional active Board support as i see it. So for me, they strengthen the board with two solid appointments and I'm adding for the long term. None of the current issues are insurmountable IMO but they need to recognise them that is all and do something about it, as i keep saying, you don't know what you don't know, Until then short term the share price will be volatile and it will remain a traders play. That's how i see it at the moment
Posted at 30/6/2022 11:59 by tonythemanwithnoname
This reminds me when GM was in charge what BS did he speak.. ValiRx PLC ("ValiRx" or the "Company") Placing of 15,000,000 Ordinary Shares at issue price of 10p per share Proposed Broker Option for up to 10,000,000 Ordinary Shares at the Issue Price London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces a Placing to raise GBP1.5 million (before expenses) through the allotment and issue of 15,000,000 New Ordinary Shares at the Issue Price of 10 pence per Ordinary Share. In addition, to provide shareholders and other investors who did not initially have the opportunity to participate in the Placing to now do so, the Company is granting an option (the "Broker Option") allowing additional subscriptions up to GBP1.0 million with priority given to existing shareholders of the Company. The net proceeds from the Fundraising will be used to provide working capital for the Group to continue development of its assets, as well as strengthen its balance sheet with a view to pursuing its acquisitive tCRO strategy. Fundraising highlights -- Placing to raise GBP1.5 million from new and existing shareholders to provide working capital for the Group and strengthen its balance sheet to progress the Company's acquisitive tCRO (Translational Contract Research Organisation) model -- Conditional Broker Option to provide shareholders and other investors who did not initially have the opportunity to participate in the Placing to participate in the Fundraise for up to GBP1.0 million -- Issue Price of 10p per share represents a discount of 38% to closing market price on last practicable Business Day prior to this announcement
Valirx share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
VAL
Valirx
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220928 16:30:26